Engineered botulinum neurotoxins as new therapeutics

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 27-51

  Masuyer, Geoffrey ^a   Chaddock, John A ^b   Foster, Keith A ^b   Ravi Acharya, K ^a  

^a University of Bath   (United Kingdom)

^b SYNTAXIN LTD   (United Kingdom)

Author keywords

Biopharmaceuticals; Hypersecretory disorders; Intracellular transporter; Protein engineering

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; N ETHYLMALEIMIDE SENSITIVE FACTOR; SNARE PROTEIN;

BOTULISM; CHOLINERGIC NERVE; CRYSTAL STRUCTURE; DRUG MECHANISM; EXOCYTOSIS; HUMAN; MUTAGENESIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW;

ANIMALS; BOTULINUM TOXINS; CELL LINE; EXOCYTOSIS; HUMANS; NEUROTOXINS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEOLYSIS; SNARE PROTEINS; SYNAPTIC TRANSMISSION;

EID: 84891884282     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135935     Document Type: Review

References (116)

1. Hatheway CL. 1990. Toxigenic clostridia. Clin. Microbiol. Rev. 3:66-98
2. Caya JG, Agni R, Miller JE. 2004. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch. Pathol. Lab. Med. 128:653-62
3. Coffield JA, Bakry N, Zhang RD, Carlson J, Gomella LG, Simpson LL. 1997. In vitro characterization of botulinum toxin types A, C and Daction on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J. Pharmacol. Exp. Ther. 280:1489-98
4. Hedeland M, Moura H, Båverud V, Woolfitt AR, Bondesson U, Barr JR. 2011. Confirmation of botulism in birds and cattle by the mouse bioassay and Endopep-MS. J. Med. Microbiol. 60:1299-305
5. Collins MD, East AK. 1998. Phylogeny and taxonomy of the foodborne pathogen Clostridium botulinum and its neurotoxins. J. Appl. Microbiol. 84:5-17
6. Kubota T, Yonekura N, Hariya Y, Isogai E, Isogai H, et al. 1998. Gene arrangement in the upstream region of Clostridium botulinum type E and Clostridium butyricum BL6340 progenitor toxin genes is different from that of other types. FEMS Microbiol. Lett. 158:215-21
7. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, et al. 2007. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J. Bacteriol. 189:818-32
8. Moriishi K, Koura M, Abe N, Fujii N, Fujinaga Y, et al. 1996. Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochim. Biophys. Acta 1307:123-26
9. Barash JR, Arnon SS. 2004. Dual toxin-producing strain of Clostridium botulinum type Bf isolated from a California patient with infant botulism. J. Clin. Microbiol. 42:1713-15
10. Smith TJ, Lou J, Geren I, Forsyth CM, Tsai R, et al. 2005. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73:5450-57
11. Hill KK, Xie G, Foley BT, Smith TJ, Munk AC, et al. 2009. Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains. BMC Biol. 7:66
12. Sharma SK, Ramzan MA, Singh BR. 2003. Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 41:321-31
13. Inoue K, Sobhany M, Transue TR, Oguma K, Pedersen LC, Negishi M. 2003. Structural analysis by X-ray crystallography and calorimetry of a haemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum. Microbiology 149:3361-70
14. Turton K, Chaddock JA, Acharya KR. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27:552-58
15. Montal M. 2010. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79:591-617
16. Südhof TC, Rothman JE. 2009. Membrane fusion: grappling with SNARE and SM proteins. Science 323:474-77
17. Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting exocytosis. Physiol. Rev. 80:717-66
18. Hayashi T, McMahon H, Yamasaki S, Binz T, Hata Y, et al. 1994. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J. 13:5051-61
19. Brünger AT. 2005. Structure and function of SNARE and SNARE-interacting proteins. Q. Rev. Biophys. 38:1-47
20. Sutton RB, Fasshauer D, Jahn R, Brünger AT. 1998. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution. Nature 395:347-53
21. Fasshauer D, Sutton RB, Brünger AT, Jahn R. 1998. Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs. Proc. Natl. Acad. Sci. USA 95:15781-86
22. Jahn R, Scheller RH. 2006. SNAREs-engines for membrane fusion. Nat. Rev. Mol. Cell Biol. 7:631-43
23. Lacy DB, Tepp W, Cohen AC, Das Gupta BR, Stevens RC. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:898-902
24. Swaminathan S, Eswaramoorthy S. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693-99
25. Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of clostridial neurotoxins. J. Mol. Biol. 291:1091-104
26. Drickamer K. 1988. Two distinct classes of carbohydrate recognition domains in animal lectins. J. Biol. Chem. 263:9557-60
27. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, et al. 2008. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J. Biol. Chem. 283:3997-4003
28. Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, Swaminathan S. 2009. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 386:233-45
29. Keller JE, Cai F, Neale EA. 2004. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43:526-32
30. Wang J, Meng J, Lawrence GW, Zurawski TH, Sasse A, et al. 2008. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation and protease domains to their functional characteristics. J. Biol. Chem. 283:16993-7002
31. Montecucco C. 1986. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 11:314-17
32. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. 1998. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb. Pathog. 25:91-99
33. Yowler BC, Kensinger RD, Schengrund CL. 2002. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 283:16993-7002
34. Rummel A, Marhold S, Bigalke H, Binz T. 2004. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51:631-43
35. Kroken AR, Karalewitz AP, Fu Z, Kim JJ, Barbieri JT. 2011. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 286:26828-37
36. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, et al. 1996. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378:253-57
37. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, et al. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-96
38. Nowack A, Yao J, Custer KL, Bajjalieh SM. 2010. SV2 regulates neurotransmitter release via multiple mechanisms. Am. J. Physiol. Cell Physiol. 299:C960-67
39. Binz T, Rummel A. 2009. Cell entry strategy of clostridial neurotoxins. J. Neurochem. 109:1584-95
40. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, et al. 2007. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. USA 104:359-64
41. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, et al. 2006. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444:1096-100
42. Jin R, Rummel A, Binz T, Brünger AT. 2006. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444:1092-95
43. Swaminathan S. 2011. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J. 278:4467-85
44. Karalewitz AP, Kroken AR, Fu Z, Baldwin MR, Kim JJ, Barbieri JT. 2010. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 49:8117-26
45. Strotmeier J, Lee K, Völker AK, Mahrhold S, Zong Y, et al. 2010. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 431:207-16
46. Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR. 2009. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48:5631-41
47. Schmitt J, Karalewitz AP, Benefield DA, Mushrush DJ, Pruitt RN, et al. 2010. Structural analysis of botulinum neurotoxin type G receptor binding. Biochemistry 49:5200-5
48. Stenmark P, Dong M, Dupuy J, Chapman ER, Stevens RC. 2010. Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding. J. Mol. Biol. 397:1287-97
49. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC. 2008. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 4:e1000129
50. Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C. 2009. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem. Biophys. Res. Commun. 380:76-80
51. Donovan JJ, Simon MI, Montal M. 1982. Insertion of diphtheria toxin into and across membranes: role of phosphoinositide asymmetry. Nature 298:669-72
52. Masuyer G, Thiyagarajan N, James PL, Marks PMH, Chaddock JA, Acharya KR. 2009. Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A. Biochem. Biophys. Res. Commun. 381:50-53
53. Masuyer G, Beard M, Cadd VA, Chaddock JA, Acharya KR. 2011. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B. J. Struct. Biol. 174:52-57
54. Schmid MF, Robinson JP, Das Gupta BR. 1993. Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles. Nature 364:827-30
55. Colasante C, Rosseto O, Morbiato L, Pirazzini M, Molgó J, Montecucco C. 2013. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol. Neurobiol. 48:120-27
56. Sun S, Suresh S, Liu H, Tepp WH, Johnson EA, et al. 2011. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe 10:237-47
57. Koriazova LK, Montal M. 2003. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 10:13-18
58. Fischer A, Montal M. 2007. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. USA 104:10447-452
59. Fischer A, Mushrush DJ, Lacy DB, Montal M. 2008. Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog. 4:e1000245
60. Fischer A, Montal M. 2007. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 282:29604-11
61. Fischer A. 2013. Synchronized chaperone function of botulinum neurotoxin domains mediates light chain translocation into neurons. Curr. Top. Microbiol. Immunol. 12:80-84
62. Fernandez-Salas E, Steward LE, Ho H, Garay PE, Sun SW, et al. 2004. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl. Acad. Sci. USA 101:3208-13
63. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, et al. 2010. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. USA 107:16554-59
64. Agarwal R, Eswaramoorthy S, Kumaran D, Binz T, Swaminathan S. 2004. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212→Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 43:6637-44
65. Agarwal R, Binz T, Swaminathan S. 2005. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry 44:11758-65
66. Segelke B, Knapp M, Kadkhodayan S, Balhorn R, Rupp B. 2004. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity. Proc. Natl. Acad. Sci. USA 101:6888-93
67. Arndt JW, Yu W, Bi F, Stevens RC. 2005. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry 44:9574-80
68. Arndt JW, Chai Q, Christian T, Stevens RC. 2006. Structure of botulinum neurotoxin type D light chain at 1.65 Å resolution: repercussions for VAMP-2 substrate specificity. Biochemistry 45:3255-62
69. Jin R, Sikorra S, Stegmann CM, Pich A, Binz T, Brünger AT. 2007. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry 46:10685-93
70. Binz T, Bade S, Rummel A, Kollewe A, Alves J. 2002. Arg362 and Tyr365 of the botulinum neurotoxin type A light chain are involved in transition state stabilization. Biochemistry 41:1717-23
71. Agarwal R, Binz T, Swaminathan S. 2005. Analysis of active site residues of botulinum neurotoxin E by mutational, functional and structural studies: Glu335Gln is an apoenzyme. Biochemistry 44:8291-302
72. Breidenbach MA, Brünger AT. 2004. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432:925-29
73. Binz T. 2013. Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr. Top. Microbiol. Immunol. 364:139-57
74. Rossetto O, Schiavo G, Montecucco C, Poulain B, Deloye F, et al. 1994. SNAREmotif and neurotoxins. Nature 372:415-16
75. Fasshauer D, Bruns D, Shen B, Jahn R, Brünger AT. 1997. A structural change occurs upon binding of syntaxin to SNAP-25. J. Biol. Chem. 272:4582-90
76. Chen S, Hall C, Barbieri JT. 2008. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J. Biol. Chem. 283:21153-59
77. Sikorra S, Henke T, Galli T, Binz T. 2008. Substrate recognition mechanism of VAMP/synaptobrevincleaving clostridial neurotoxins. J. Biol. Chem. 283:21145-52
78. Agarwal R, Schmidt JJ, Stafford RG, Swaminathan S. 2009. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat. Struct. Mol. Biol. 16:789-94
79. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, et al. 2003. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A: basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 278:1363-71
80. Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM, et al. 2011. A dileucine in the protease domain of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J. Biol. Chem. 286:6375-85
81. Brünger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, Montal M. 2007. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 3:1191-94
82. Galloux M, Vitrac H, Montagner C, Raffestin S, Popoff MR, et al. 2008. Membrane interaction of botulinum neurotoxin A translocation (T) domain: The belt region is a regulatory loop for membrane interaction. J. Biol. Chem. 283:27668-76
83. Scott AB. 1980. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044-49
84. Apostolidis A, Haferkamp A, Aoki KR. 2006. Understanding the role of botulinum toxin A in the treatment of the overactive bladder-more than just muscle relaxation. Eur. Urol. Suppl. 5:670-78
85. Moore AP. 2007. Expanding clinical uses of botulinum neurotoxins. In Treatments from Toxins: The Therapeutic Potential of Clostridial Neurotoxins, ed KA Foster, P Hambleton, CC Shone, pp. 163-94. Boca Raton, FL: CRC
86. Chen S. 2012. Clinical uses of botulinum neurotoxins: current indications, limitations, and future developments. Toxins 4:913-39
87. Barnes MP. 2007. Introduction to clinical use of botulinum neurotoxins. In Treatments from Toxins: The Therapeutic Potential of Clostridial Neurotoxins, ed KA Foster, P Hambleton, CC Shone, pp. 139-62. Boca Raton, FL: CRC
88. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. 1997. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci. Lett. 224:91-94
89. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, et al. 1995. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 45:506-8
90. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett. 256:135-38
91. Chen S, Barbieri JT. 2009. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl. Acad. Sci. USA 106:9180-84
92. Wang D, Zhang Z, Dong M, Sun S, Chapman ER, Jackson MB. 2011. Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin. Biochemistry 50:2711-13
93. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, et al. 2006. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 362:733-42
94. Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, et al. 2012. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochem. J. 444:59-67
95. Rummel A, Marhold S, Bigalke H, Binz T. 2011. Exchange of the HCC domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS J. 278:4506-15
96. Wang J, Zurawski TH, Meng J, Lawrence GW, Aoki KR, et al. 2012. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J. 26:5035-48
97. Goodnough MC, Oyler G, Fishman PS, Johnson EA, Neale EA, et al. 2002. Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett. 513:163-68
98. Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G, et al. 2004. Botulinum neurotoxin typeD enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J. Neurochem. 91:1461-72
99. Box M, Parks DA, Knight A, Hale C, Fishman PS, Fairweather NF. 2003. Amulti-domain protein system based on the HCfragment of tetanus toxin for targeting DNAto neuronal cells. J. Drug Target. 11:333-43
100. Drachman DB, Adams RN, Balasubramanian U, Lu Y. 2010. Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progress. Toxins 2:2872-89
101. Darios F, Niranjan D, Ferrari E, Zhang F, Soloviev M, et al. 2010. SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proc. Natl. Acad. Sci. USA 107:18197-201
102. Ferrari E, Maywood ES, Restani L, Caleo M, Pirazzini M, et al. 2011. Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity. Toxins 3:345-55
103. Stancombe PR, Masuyer G, Birch-Machin I, Beard M, Foster KA, et al. 2012. Engineering Clostridium botulinum endopeptidase and translocation domains with SNARE peptides. FEBS J. 279:515-23
104. Masuyer G, Stancombe PR, Chaddock JA, Acharya KR. 2011. Structures of engineered Clostridium botulinum neurotoxin derivatives. Acta Crystallogr. F 67:1466-72
105. Shone CC, Hambleton P, Melling J. 1985. Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments: proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur. J. Biochem. 151:75-82
106. Shone CC, Hambleton P, Melling J. 1987. A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles. Eur. J. Biochem. 167:175-80
107. Chaddock JA, Herbert MH, Ling RJ, Alexander FC, Fooks SJ, et al. 2002. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. 25:219-28
108. Sutton JM, Wayne J, Scott-Tucker A, O'Brien SM, Marks PMH, et al. 2005. Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications. Protein Expr. Purif. 40:31-41
109. Foster KA. 2009. Engineered toxins: new therapeutics. Toxicon 54:587-92
110. Chaddock JA, Purkiss JR, Duggan MJ, Quinn CP, Shone CC, Foster KA. 2000. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18:147-55
111. Chaddock JA, Purkiss JR, Friis LM, Broadbridge JD, Duggan MJ, et al. 2000. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. 68:2587-93
112. Duggan MJ, Quinn CP, Chaddock JA, Purkiss JR, Alexander FC, et al. 2002. Inhibition of release of neurotransmitters from dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem. 277:34846-52
113. Foster KA, Adams EJ, Durose L, Cruttwell CJ, Marks E, et al. 2006. Re-engineering the target specificity of clostridial neurotoxins: a route to novel therapeutics. Neurotox. Res. 9:101-7
114. Foster KA, Chaddock JA. 2010. Targeted secretion inhibitors-innovative protein therapeutics. Toxins 2:2795-815
115. Somm E, Bonnet N, Martinez A, Marks PMH, Cadd VA, et al. 2012. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J. Clin. Investig. 122:3295-306
116. Yeh FL, Zhu Y, Tepp WH, Johnson EA, Bertics PJ, Chapman ER. 2011. Retargeted clostridial neurotoxins as novel agents for treating chronic diseases. Biochemistry 50:10419-21